scispace - formally typeset
A

Ana S. Leal

Researcher at Michigan State University

Publications -  31
Citations -  689

Ana S. Leal is an academic researcher from Michigan State University. The author has contributed to research in topics: Cancer & Bexarotene. The author has an hindex of 11, co-authored 25 publications receiving 527 citations. Previous affiliations of Ana S. Leal include University of Coimbra & Dartmouth College.

Papers
More filters
Journal ArticleDOI

Ursane-type pentacyclic triterpenoids as useful platforms to discover anticancer drugs

Jorge A. R. Salvador, +4 more
- 06 Nov 2012 - 
TL;DR: This review highlights the potential of natural and semisynthetic ursane-type triterpenoids as candidates for the design of multi-target bioactive compounds, with focus on their anticancer effects.
Journal ArticleDOI

Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment

Jorge A. R. Salvador, +7 more
- 14 Jul 2017 - 
TL;DR: A number of semisynthetic derivatives of oleanane-, ursane- and quinone methide friedelane-type PTs with anticancer activity have been synthetized aiming to improve their therapeutic activity and pharmacokinetic properties, and decrease their toxicity.
Journal ArticleDOI

Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer

Ana S. Leal, +6 more
- 28 May 2017 - 
TL;DR: These drugs suppressed the production of nitric oxide and a variety of inflammatory cytokines, including IL-6, CCL2, and GM-CSF, in both immune and pancreatic cancer cells in vitro.
Journal ArticleDOI

Synthesis of novel ursolic acid heterocyclic derivatives with improved abilities of antiproliferation and induction of p53, p21waf1 and NOXA in pancreatic cancer cells

Ana S. Leal, +4 more
- 01 Oct 2012 - 
TL;DR: A series of new heterocyclic derivatives of ursolic acid 1 were synthesized and evaluated for their antiproliferative activity against AsPC-1 pancreatic cancer cells and compound 32 is the most active compound with an IC(50) of 1.9 μM which is sevenfold more active than ursolics acid 1.
Book ChapterDOI

Highlights of Pentacyclic Triterpenoids in the Cancer Settings

Jorge A. R. Salvador, +6 more
- 01 Jan 2014 - 
TL;DR: In this article, the authors presented the most relevant properties that contribute to the antitumor activity of the referred natural triterpenoids and their semisynthetic derivatives and their derivatives.